martedì, 21 marzo 2023

Notizie AIOM – anno XVI n. 683

3 luglio 2018 – Chiusura Registro di Monitoraggio Pazopanib (Novartis) (RCC)

Scheda informativa condivisa da ISS, PMA, AIMAC e AIOM

Suggerimenti semplici su come preservare la fertilità prima dei trattamenti antitumorali, firmate da Istituto Superiore di Sanità (ISS), Registro Nazionale di Procreazione Medicalmente Assistita (PMA), Associazione Italiana Malati di Cancro, parenti e amici ...
Leggi tutto

6 luglio 2018 – Incarichi e consulenze a soggetti esterni – aggiornamento sezione

6 luglio 2018 – Procedura di applicazione Managed Entry Agreement – Obinutuzumab (Roche) (LLC)

6 luglio 2018 – Attivazione del Registro Obinutuzumab (Roche) (LLC)

Endocrine Society Issues Guideline to Address the Risk of Endocrine Disorders Among Survivors of Childhood Cancers

July 5, 2018 - To address a growing risk of endocrine disorders among childhood cancer survivors, the Endocrine Society has published the “Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline,” ...
Leggi tutto

New Guide Helps Clinicians Navigate Immunotherapy in Merkel Cell Carcinoma

July 6, 2018 - Fred Hutchinson Cancer Research Center researchers have published a new guide to help clinicians navigate a recent revolution in care for advanced Merkel cell carcinoma. The guide was published in JNCCN–Journal of the National Comprehensive Cancer Network, ...
Leggi tutto

FDA Grants Priority Review for Glasdegib in Patients With Previously Untreated AML

July 7, 2018 - The U.S. Food and Drug Administration (FDA) recently accepted a new drug application and granted Priority Review designation for glasdegib, an investigational oral smoothened inhibitor being evaluated for the treatment of adult patients with previously untreated ...
Leggi tutto

Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)

This open-label, phase III trial compared chemoradiation followed by surgery with or without neoadjuvant and adjuvant cetuximab in patients with resectable esophageal carcinoma. Patients were randomly assigned (1 : 1) to two cycles of chemotherapy (docetaxel 75 mg/m2, ...
Leggi tutto

FDA Accepts sBLA for Pembrolizumab as Adjuvant Therapy in Advanced Melanoma

July 5, 2018 - The U.S. Food and Drug Administration (FDA) has accepted for standard review a new supplemental biologics license application (sBLA) for pembrolizumab as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma. The Prescription ...
Leggi tutto